PodcastIntel
Sign in Get Started Free
The Long Run with Luke Timmerman
The Long Run with Luke Timmerman

Ep192: Kate Haviland on Following the Science to Precision Immunology

Jan 8, 2026 · 01:26:06
Listen to Episode
✨ AI Summary
  • Kate Haviland discusses Blueprint Medicines' transition to precision immunology.
  • The company was acquired by Sanofi for $9.5 billion.
  • Focus on scientific evolution and strategic growth in biotech.

Guests on This Episode

KH
Kate Haviland
1 podcast appearance

More from The Long Run with Luke Timmerman

The Long Run with Luke Timmerman
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Oct 7, 2026 · 01:06:37
The Long Run with Luke Timmerman
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Sep 23, 2026 · 01:03:57
The Long Run with Luke Timmerman
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Sep 9, 2026 · 01:36:12
The Long Run with Luke Timmerman
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Aug 25, 2026 · 01:07:17
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to The Long Run with Luke Timmerman and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →